Forum Topics EIQ EIQ Strawman Interview

Pinned straw:

Added a month ago

Great interview as always Strawman.

COO Philip seemed to get a little vague when he was asked specific questions. For example:

i) In relation to the competitor company Icardio with the product Echocardio, whom received FDA approval in the same month as EchoIQ. When asked what this competitor approval meant for EchoIQ, he responded they were about “measurement”. How the two FDA approved software systems differed and why the EIQ product was superior was not well explained.

ii)       When asked the question in relation to progress of the Hydrix (HYD) 3 year agreement signed in April 2023 with EIQ to sell the “Echosolve” software in Australia NZ and Singapore, he was again vague. Philip talked about a pilot being extended out with Hendrix and these things taking time to get moving.  Well, the total operational revenue in FY 24 was only $44,500. This does not speak to a business or relationship that is firing.  In addition, you would think the recent FDA approval might have stirred some interest in the Australian market Philip could expand on.  

iii) Philip was asked about the announced (16/9/24) Icardio.ai collaboration with Abbott to develop artificial intelligence for Abbott’s imaging devices, the response was along the lines of: Well, this does not preclude Abbott from entering an agreement with EIQ. A fair enough statement as far as it goes, but not one that would encourage an investor to open their wallet.

Maybe Philip is not giving too much away because of the competition and the critical stage the company is at.  Fair enough too, and maybe I am being way too harsh.  

It would be great if there is a Strawman Cardio somewhere out there in the medical heartland (note the ingenious word pun), or someone knows one whom can give an objective opinion on EIQ’s software?  Because F*&^%ed if I know what to think.

Aaronfzr
Added a month ago

I use echo myself a bit in clinical practice, and I still dont understand what exactly the product does.

My best guess is that it is an app or a plugin to existing echo software (they all save echo pictures in the same format), which applies the algorithm to the echo loops (videos) to spit out a diagnosis or classification of lesion severity. My impression is (despite the company hype) this will be an aid to workflow / speed rather than diagnostic accuracy

16

Strawman
Added a month ago

Ah, always good to get a user's experience @Aaronfzr !

Just to make sure we're on the same page, — are you maybe thinking of EchoGo by Ultromics? Echo IQ’s product is called EchoSolv, and it works a bit differently. Instead of analyzing echo images or loops, EchoSolv interprets echocardiogram measurements (something Philip pulled me up on today too!).

13

Aaronfzr
Added a month ago

I was thinking of EIQ echosolv, but this shows how little I actually understand of the product (and believe me, Ive tried to figure it out). Probably they aren't marketing to potential end-users.

This is an interesting and important clarification though.

To humans, Echo studies just videos. The measurements come from the sonographer or cardiologist who looks at the images and makes various measurements (shape of this, diameter of that). There is a surprising amount of inconsistency between users deciding which particular bit counts and which doesnt (hence why echo is "user-dependent" or subject to "inter-individual variability). If EIQ is taking the measurements created by sonographers, and plugging them into an algorithm, Id be worried the results are susceptible to user error and Im not that excited.


If he meant though, that they use the raw echo data used to create the images/loops, and generating their own measurements, then that is very interesting. It takes out what has always been a limitation - the human eye's ability to differentiate between various shadows created as a visual representation of the underlying data!

15

Chagsy
Added a month ago

Exactly @Aaronfzr !

The whole point about such radiological studies and measurements is the “kappa” - inter-observer variability. I’m afraid I haven’t done the work on this one to offer an informed view, but it is usually an under-reported statistic. Often because a low Kappa basically undermines the whole thesis. So they don’t publish it.

c

17
Strawman
Added a month ago

Good points @Scoonie, and thanks for putting through some great questions for the meeting.

There really is a lot of potential here. I have no direct experience with the industry (obviously), but the addressable market and value prop seem very compelling. But then again, doesnt it always!

The hard point is knowing when a company like this goes from interesting tech to commercial success. It's genuinely made some good progress in the time since we last spoke -- but as Philip said, it's slow going by nature. I suspect it will be at least ~18 months before we get any early evidence of sales traction, and another 6-9 more from there to see if there's any momentum.

I put it into the same camp as EMVision actually. (And i have a tiny 0.8% holding there). It's one of those situations where it could easily 10-20x from here...or it never gets traction and it slowly erodes 90% of it's value over the next 5-10 years.

I think the way to approach these situations is to average up as the thesis plays out, with a preparedness to dump the lot if ever it looks like the vision isnt going to be realized.

To your question @nessy (on other straw), I took it that the next FDA approval will likely follow a similar timeline. So maybe a year at the earliest? depending on the data they can submit.

15

GazD
Added 3 weeks ago

Hi everyone @Aaronfzr @Scoonie @Strawman @Chagsy , I finally got to watching this meeting back having been busy doing some exams on, you guessed it, echocardiography! Now I'm absolutely not an expert but I am interested enough to take a look at this business.

I didn't find Philip as vague as you @Scoonie in that he answered the question about ICardio clearly. He explained that their software is analaysing the images themselves and deriving measurements as opposed to EchoIQ whose tech is entirely about assessing the data points (as collected by the songrapher) using a proprietary algorithm. He also made the point that a software which improved the acquisition of images would likely benefit EchoIQ as they would feed better data into the algorithm. I can conceive of a world whereby there was a health insurance reimbursement code that reimbursed for 1) Software based assessment of Echo images and a separate one for 2) Software bases assessment of Echo datapoints. I could also see a world where both of these small providers might be swallowed up by a much bigger business (Phillps, GE, Siemens etc).

One point which resonated me with regards heart failure is the potential difficulties in diagnosing it. Clearly cardiologists are in a better position than I (as an anaesthetist) to make this call, however, it can become very complex very quickly looking at different data points with regards diastolic dysfunction for example and I can absolutely believe an AI algorithm would do it better than most humans and the two combined would be even better as discussed. Heart failure is a big big deal and even a small improvement in detection and classification would be valuable from a human and financial perspective.

For me it's not quite investable yet having been burnt by biotechnology in the past (looking at you paradigm) but I will watch with interest.

20